Indoco Remedies Ltd. announced the receipt of tentative US FDA approval for Abbreviated New Drug Application (ANDA) for canagliflozin tablets 100 mg and 300 mg, a generic equivalent of the Reference Listed Drug, Invokana tablets 100 mg and 300 mg, of Janssen Pharmaceuticals, Inc.
This product will be manufactured by Indoco Remedies Limited, at their manufacturing facility located at Goa (Plant -I) in India.
Canagliflozin improves glycemic control in adults with type 2 diabetes mellitus.
Commenting on the achievement, Aditi Panandikar, managing director said, “Besides reflecting the capability of Indoco Remedies to deliver products of high-quality standards, this development also provides impetus to our growth aspirations in an important market such as the US.”
Indoco is a fully integrated, research-oriented pharmaceutical company with presence in 55 countries. The Company’s turnover is US$ 200 million with a human capital of 6,000 employees, including over 400 skilled scientists and field staff who are the strength of the organization.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!